Edition

Michael Montess

2

0

Assistant Professor, Dalla Lana School of Public Health & Joint Centre for Bioethics, University of Toronto

The HIV prevention drug cabotegravir, which is delivery by injection every eight weeks, is not yet available in Canada. (Shutterstock)

December 18, 2022

Long‑acting injectable PrEP is a big step forward in HIV prevention

Michael Montess, Western University; Darrell Tan, University of Toronto, and Nathan John Lachowsky, University of Victoria

The next step in HIV prevention — long-acting injectable pre-exposure prophylaxis (PrEP) — is not yet available in Canada, a year after its approval in the U.S.

Thousands gather in downtown Toronto in 2006 for a candlelight vigil to remember those who have died from AIDS. (CP PHOTO/Nathan Denette)

May 13, 2021

HIV survivors’ stories show the loss, resilience and activism of the early years of AIDS pandemic

Michael Montess, University of Victoria and Nathan John Lachowsky, University of Victoria

The HIV In My Day project preserves the early history of the HIV/AIDS pandemic through the personal stories of long-term survivors and caregivers.

Contact Michael for

General
Media request
Speaking request
Consulting / Advising
Research collaboration
Research supervision

Location: Toronto, Canada
Website
Article Feed
ORCID
Joined June 25, 2020